<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">BMC Res Notes</journal-id>
      <journal-id journal-id-type="iso-abbrev">BMC Res Notes</journal-id>
      <journal-title-group>
        <journal-title>BMC Research Notes</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1756-0500</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">27113212</article-id>
      <article-id pub-id-type="pmc">4845314</article-id>
      <article-id pub-id-type="publisher-id">2052</article-id>
      <article-id pub-id-type="doi">10.1186/s13104-016-2052-0</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Acute exacerbation of interstitial pneumonia associated with rheumatoid arthritis during the course of treatment for <italic>Pneumocystis jirovecii</italic> pneumonia: a case report</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Kuroda</surname>
            <given-names>Takeshi</given-names>
          </name>
          <address>
            <phone>+81-25-227-2200</phone>
            <email>kurodat@med.niigata-u.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Takeuchi</surname>
            <given-names>Hiroyuki</given-names>
          </name>
          <address>
            <email>philosophos0317@live.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nozawa</surname>
            <given-names>Yukiko</given-names>
          </name>
          <address>
            <email>yukikonzw0820@yahoo.co.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sato</surname>
            <given-names>Hiroe</given-names>
          </name>
          <address>
            <email>hiroe77212@hotmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nakatsue</surname>
            <given-names>Takeshi</given-names>
          </name>
          <address>
            <email>takeshinakatsue@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wada</surname>
            <given-names>Yoko</given-names>
          </name>
          <address>
            <email>yoko.wada@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Moriyama</surname>
            <given-names>Hiroshi</given-names>
          </name>
          <address>
            <email>hiroshim@med.niigata-u.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nakano</surname>
            <given-names>Masaaki</given-names>
          </name>
          <address>
            <email>manakano@clg.niigata-u.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff3"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Narita</surname>
            <given-names>Ichiei</given-names>
          </name>
          <address>
            <email>naritai@med.niigata-u.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <aff id="Aff1"><label/>Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-Dori, Chuoku, Niigata City, 951-8510 Japan </aff>
        <aff id="Aff2"><label/>Department of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-Dori, Chuoku, Niigata City, 951-8510 Japan </aff>
        <aff id="Aff3"><label/>Department of Medical Technology, School of Health Sciences, Faculty of Medicine, Niigata University, 2-746 Asahimachi-Dori, Chuoku, Niigata City, Niigata 951-8518 Japan </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>26</day>
        <month>4</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>26</day>
        <month>4</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2016</year>
      </pub-date>
      <volume>9</volume>
      <elocation-id>240</elocation-id>
      <history>
        <date date-type="received">
          <day>31</day>
          <month>1</month>
          <year>2016</year>
        </date>
        <date date-type="accepted">
          <day>19</day>
          <month>4</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Kuroda et al. 2016</copyright-statement>
        <license license-type="OpenAccess">
          <license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Background</title>
          <p><italic>Pneumocystis jirovecii</italic> pneumonia (PCP) is potentially fatal infectious complication in patients with rheumatoid arthritis (RA) during immunosuppressive therapy. Hospital survival due to human immunodeficiency virus&#x2014;unrelated PCP reaches to 60&#xA0;%. The high mortality rate results from difficulties in establishing an early diagnosis, concurrent use of prophylactic drugs, possible bacterial coinfection. We herein report a case of PCP in RA patients who developed the architectural distortions of lung in spite of combined modality therapy.</p>
        </sec>
        <sec>
          <title>Case presentation</title>
          <p>A 73-year-old Japanese woman with RA was admitted with shortness of breath. Five weeks previously, she had been started on etanercept in addition to methotrexate (MTX). Chest computed tomography (CT) demonstrated diffuse ground glass opacities distributed throughout the bilateral middle to lower lung fields, and serum &#x3B2;-<sc>d</sc>-glucan was elevated. Bronchoalveolar lavage fluid revealed no <italic>P. jirovecii</italic>, but the organism was detected by polymerase chain reaction method. Trimethoprim/sulfamethoxazole was administered with methylprednisolone pulse therapy. However, the follow-up chest X-ray and chest CT demonstrated aggravation of the pneumonia with architectural distortions. Additional direct hemoperfusion with polymyxin B-immobilized fibers and intravenous cyclophosphamide therapy were insufficiently effective, and the patient died on day 25.</p>
        </sec>
        <sec>
          <title>Conclusion</title>
          <p>The architectural distortions of lung should be considered as a cause of death of PCP. For this reason, a high suspicion of this infectious complication must be kept in mind in order to establish an early diagnosis and treatment in patients with RA managed with MTX and biologics.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Rheumatoid arthritis</kwd>
        <kwd>Etanercept</kwd>
        <kwd><italic>Pneumocystis jirovecii</italic> pneumonia</kwd>
        <kwd>Architectural distortions</kwd>
        <kwd>Case report</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s) 2016</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Background</title>
      <p>Pneumonia is among the most frequent potentially fatal infectious complication in patients who are immunocompromised. The incidence of <italic>Pneumocystis jirovecii</italic> pneumonia (PCP) is estimated to be 0.2&#x2013;0.5&#xA0;% in patients with rheumatoid arthritis (RA) undergoing therapy with biologics in Japan [<xref ref-type="bibr" rid="CR1">1</xref>]. The most frequent symptoms are progressive dyspnea, dry cough and a low-grade fever [<xref ref-type="bibr" rid="CR2">2</xref>]. Interstitial lung disease (ILD) is a well-established and debilitating extra-articular manifestation of RA. ILD is the primary form of pulmonary involvement in RA, with a prevalence ranging from 4 to 68&#xA0;%, mostly in the 50&#x2013;60-year age group [<xref ref-type="bibr" rid="CR3">3</xref>]. Respiratory symptoms may precede the onset of articular symptoms in 10&#x2013;20&#xA0;% of cases [<xref ref-type="bibr" rid="CR4">4</xref>]. Pulmonary fibrosis including multiple thin-walled cysts, which varies in occurrence and severity, is radiographically evident in 10&#x2013;34&#xA0;% with PCP patients [<xref ref-type="bibr" rid="CR5">5</xref>]. In patients with acquired immune deficiency syndrome (AIDS), morphological changes at the late stage of infection have been frequently reported. However, there have been few reports on such late morphological changes in non- human immunodeficiency virus (HIV) patients [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR6">6</xref>&#x2013;<xref ref-type="bibr" rid="CR9">9</xref>]. The most common pattern in the early phase of the lung disease is wide distribution of ground glass opacities (GGOs) with a preference for the apical and central lung regions [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR10">10</xref>&#x2013;<xref ref-type="bibr" rid="CR12">12</xref>]. There are few data about the course, duration and morphological changes in patients with PCP who are not immunocompromised due to HIV. Here we report a case of PCP associated with the use of etanercept in a patient with RA who developed architectural distortions.</p>
    </sec>
    <sec id="Sec2">
      <title>Case report</title>
      <p>A 73-year-old Japanese woman had been diagnosed as having RA 5&#xA0;years before presentation and was initially treated with etanercept at 50&#xA0;mg/week. Her family history included no consanguinity or collagen diseases. Two years before presentation, she had suffered tuberculous cervical lymphadenitis and had stopped taking etanercept because of remission. After 1&#xA0;year, she was diagnosed as having interstitial pneumonia by chest computed tomography (CT) (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>a). Her RA disease activity gradually increased, and she was started on methotrexate (MTX) at 6&#xA0;mg/week 18&#xA0;months before presentation. She was referred to our hospital because of her increasing disease activity. Because control of the RA was incomplete, the dose of MTX was gradually increased to 10&#xA0;mg/week. Two month before treatment of biologics, chest X-ray was performed and diagnosed as having interstitial pneumonia again (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>b). As the disease was refractory, biological therapy with etanercept at 25&#xA0;mg/week was readministered when the RA was diagnosed as class 2, stage II. Five weeks later, she presented at our hospital complaining of cough and shortness of breath that had persisted for 2&#xA0;weeks. On admission, the patient&#x2019;s body temperature was 35.7&#xA0;&#xB0;C and her respiratory rate was 18&#xA0;breaths/min. Chest auscultation revealed bilateral fine crackles. Arterial blood gas analysis on 2L of O<sub>2</sub> via a nasal cannula showed a pH of 7.41, PaO<sub>2</sub> 89.3&#xA0;Torr, PaCO<sub>2</sub> 38.1&#xA0;Torr, and HCO<sub>3</sub><sup>&#x2212;</sup> 23.7&#xA0;mmol/L. Laboratory examinations revealed a white blood cell count of 6930/&#x3BC;L (neutrophils: 97.0&#xA0;%, lymphocytes: 3.0&#xA0;%, monocytes: 0.0&#xA0;%, eosinophils: 0.0&#xA0;%, basophils: 0.0&#xA0;%), lactate dehydrogenase 424&#xA0;IU/L, C-reactive protein 20.7&#xA0;mg/dL, procalcitonin 0.83&#xA0;ng/mL, sialylated carbohydrate antigen Krebs von den Lungen-6 (KL-6) 1035&#xA0;U/mL, surfactant protein D (SP-D) 262.9&#xA0;ng/mL, and &#x3B2;-<sc>d</sc>-glucan 158&#xA0;U/mL. Although the CT findings did not suggest malignancy, the levels of tumor markers such as carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), and soluble interleukin-2 receptor (sIL-2R) were elevated at 8.5&#xA0;ng/mL, 799 and 2954&#xA0;U/mL, respectively. In addition, an HIV test had a negative result. A chest X-ray showed demonstrated GGOs in the middle and lower lung fields. High-resolution CT (HRCT) showed GGOs with thickened interlobular septa and traction bronchiectasis (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>). We suspected that the patient had PCP, but MTX-induced lung disease and cytomegalovirus pneumonia were included in the differential diagnosis. We then stopped the MTX therapy and started the patient on trimethoprim/sulfamethoxazole (SMX/TMP) at a TMP dose of 720&#xA0;mg daily with empirical meropenem antibiotic therapy. On the 2nd hospital day, chest CT was performed again and this showed that CT-attenuation of pulmonary infiltrates had increased and the beginning of architectural distortions was evident (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>a). Bronchoscopy was performed on the third hospital day. Bronchoalveolar lavage (BAL) performed in the right middle lobe yielded 20&#xA0;mL of fluid, but no significant pathogens were cultured from it. However, the results of polymerase chain reaction (PCR) for <italic>P. jirovecii</italic> were positive, even though para-aminosalicylic acid and Grocott-Gomori methenamine silver nitrate staining of the BAL fluid revealed no <italic>P. jirovecii</italic> cysts. The patient was diagnosed as having PCP, and SMX/TMP was administered for 14&#xA0;days. On the 14th hospital day, skin eruption was observed, and this was considered to be a drug reaction; therefore SMX/TMP was switched to pentamidine. On the 14th hospital day, the patient developed dyspnea and her coughing increased. In addition, the PaO<sub>2</sub> on 3L of O<sub>2</sub> per cannula decreased to 63.4&#xA0;Torr. A chest X-ray and HRCT performed on the 8th hospital day showed an increase in GGO and parenchymal consolidations with progression of the architectural distortions and pleural effusion (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>b, c). These findings were considered to reflect an immune response due to the treatment for PCP with SMX/TMP alone. Therefore, we administered methylprednisolone from 2nd hospital day (500&#xA0;mg/day intravenously for 3&#xA0;days, followed by 250&#xA0;mg/day intravenously for 3&#xA0;days and 125&#xA0;mg/day intravenously for 3&#xA0;days). Shortness of breath was progressive and saturation of O<sub>2</sub> was decreased, necessitating readministration of methylprednisolone from the 11th hospital day (1000&#xA0;mg/day intravenously for 3&#xA0;days and then 500&#xA0;mg/day intravenously for 3&#xA0;days). In addition, direct hemoperfusion using a polymyxin B-immobilized fiber column was performed on the 11th hospital day. A chest X-ray performed on the 15th hospital day showed an increase in GGO with pleural effusion (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>d). The patient&#x2019;s respiratory condition worsened, and 500&#xA0;mg of intravenous cyclophosphamide was added on the 18th hospital day. Repeated examination of chest X-ray was performed on the 18th and 21st day and revealed no improvement (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>e, f). However, The &#x3B2;-<sc>d</sc>-glucan level was not elevated at any time during the patient&#x2019;s hospital course. It is known that the level of KL-6, a marker of interstitial lung disease, is increased in patients with PCP. The KL-6 level in our patient was 1441 U/mL on the 10th hospital day and 1585&#xA0;U/mL on the 11th hospital day. However, the patient&#x2019;s respiratory status deteriorated rapidly, and she died on the 25th day of hospitalization (Fig.&#xA0;<xref rid="Fig4" ref-type="fig">4</xref>).<fig id="Fig1"><label>Fig.&#xA0;1</label><caption><p>Chest CT and chest X-ray before treatment with biologics. <bold>a</bold> Chest CT was performed 10&#xA0;month before admission. Mild reticular shadow was observed in the bilateral lower lung. <bold>b</bold> Chest X-ray was performed 2&#xA0;month before admission. Mild reticular shadow was observed in the bilateral lower lung again</p></caption><graphic xlink:href="13104_2016_2052_Fig1_HTML" id="MO1"/></fig><fig id="Fig2"><label>Fig.&#xA0;2</label><caption><p>Chest high-resolution CT at the time of admission. A chest high-resolution CT (HRCT) showed GGOs in the lower lung field with thickened interlobular septa and traction bronchiectasis</p></caption><graphic xlink:href="13104_2016_2052_Fig2_HTML" id="MO2"/></fig><fig id="Fig3"><label>Fig.&#xA0;3</label><caption><p>Chest CT and chest X-ray in the clinical course of the patient. <bold>a</bold> Chest CT showed that CT-attenuation of pulmonary infiltrates had increased and the beginning of architectural distortions was evident (second hospital day). <bold>b</bold>, <bold>c</bold> A chest X-ray and CT showed an increase in GGO and parenchymal consolidations with progression of the architectural distortions and pleural effusion (8th hospital day). <bold>d</bold> A chest X-ray showed an increase in GGO with pleural effusion (15th hospital day). <bold>e</bold> A chest X-ray showed no change in GGO with pleural effusion in spite of direct hemoperfusion using a polymyxin B-immobilized fiber column (18th hospital day). <bold>f</bold> A chest X-ray showed an increase in GGO with pleural effusion in spite of intravenous cyclophosphamide therapy (21st hospital day)</p></caption><graphic xlink:href="13104_2016_2052_Fig3_HTML" id="MO3"/></fig><fig id="Fig4"><label>Fig.&#xA0;4</label><caption><p>Clinical course of the patient with <italic>Pneumocystis jirovecii</italic> pneumonia. Interstitial pneumonia with architectural distortions was progressed in spite of the treatment with methylprednisolone pulse therapy, direct hemoperfusion with polymyxin B-immobilized fibers and intravenous cyclophosphamide therapy</p></caption><graphic xlink:href="13104_2016_2052_Fig4_HTML" id="MO4"/></fig></p>
    </sec>
    <sec id="Sec3" sec-type="discussion">
      <title>Discussion</title>
      <p>The incidence of <italic>P. jirovecii</italic> pneumonia (PCP) is estimated to be 0.2&#x2013;0.5&#xA0;% in patients with rheumatoid arthritis (RA) undergoing therapy with biologics in Japan [<xref ref-type="bibr" rid="CR1">1</xref>]. It was indicated that combination therapies with MTX and biologics for RA are a common risk factor for PCP [<xref ref-type="bibr" rid="CR13">13</xref>]. Advanced age or existing RA lung involvement are also reportedly associated with PCP [<xref ref-type="bibr" rid="CR11">11</xref>]. Our RA patient who was treated with MTX and etenercept was over 60&#xA0;years of age and had pre-existing mild interstitial pneumonia and bronchiectasis. Additionally, she was treated with etanercept as well as MTX, but developed PCP only 1&#xA0;month after the start of etanercept administration. It is possible that the rapid change of immune status after treatment with etanercept and MTX might have led to PCP.</p>
      <p>Tasaka et al. [<xref ref-type="bibr" rid="CR12">12</xref>] have suggested that a diagnosis of PCP should be made based on a &#x3B2;-<sc>d</sc>-glucan level and positive findings for <italic>P. jirovecii</italic> in BAL fluid on PCR. It has been reported that in non-HIV-infected patients, such as those with RA with PCP, the number of organisms in the airways is relatively (10- to 100-fold) low in comparison with patients who have AIDS-related conditions [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. In the present case, the diagnosis of PCP was based on elevation the of &#x3B2;-<sc>d</sc>-glucan level and PCR positivity for <italic>P. jirovecii</italic> in BAL fluid. However, no significant pathogens were cultured from the BAL fluid, and <italic>P. jirovecii</italic> was not detected by Grocott-Gomori methenamine silver nitrate staining.</p>
      <p>Upon imaging, the initial appearance of PCP on chest CT was symmetrical, apically distributed GGOs with a perihilar location, a mosaic and consolidations pattern [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR10">10</xref>&#x2013;<xref ref-type="bibr" rid="CR12">12</xref>]. In such cases, the density of infiltrates slowly increases and a mosaic pattern with architectural distortions can evolve from GGOs if appropriate treatment is not provided. Furthermore it has been shown that GGOs rapidly improve after the treatment of specific therapy. Tokuda et al. [<xref ref-type="bibr" rid="CR16">16</xref>] reported that RA-related PCP shows both diffuse homogeneous GGOs and homogeneous or non-homogeneous GGO with sharp demarcation in the intralobular septa on chest CT. Chest CT in the present case revealed homogeneous GGOs demarcated from the non-affected lung by interlobular septa. Additionally, architectural distortions with irregular linear opacities, reticulations and traction bronchiolectasis were observed, and showed irreversible progression. The reason for these architectural distortions in unclear. With regard to fibrosis, Pareja et al. [<xref ref-type="bibr" rid="CR17">17</xref>] have suggested several effects of modulation of the host immune response by <italic>P. jirovecii</italic> itself, such as pulmonary immune clearance and other mechanisms. Additionally, it has been not completely clarified that the relationship between anti-inflammatory effects and the gas exchange abnormality, modulation of the host immune response, enhanced of effector function to <italic>P. jirovecii</italic>, enhancement of immune clearance mechanisms of lung. In more than one-third of HIV-negative PCP patients, it has recently been demonstrated that irregular linear opacities, reticulations and traction bronchiectasis were present as architectural distortions. During follow-up for PCP, these signs were reversible completely in more than two-third of them. However, postinfectious fibrosis rarely occurs following PCP. On the other hand, later expansion of lethal interstitial pneumonia despite low levels of serum &#x3B2;-<sc>d</sc>-glucan may characterize PCP in RA patients who have pre-existing pulmonary lesions. A previous pathological study of HIV-positive PCP patients revealed that the occurrence of fibrosis was variable in autopsy specimens. Either fibroblastic organization of intraalveolar exudates (fibrosing alveolitis) or PCP per se had been reported as causes or promoters of fibrosis [<xref ref-type="bibr" rid="CR7">7</xref>]. Pentamidine has frequently been used for treatment of PCP, as in the present case, but recently atovaquone has been used for both prophylaxis and treatment. The effects of pulmonary fibrosis after treatment of PCP have not been reported, and further investigations of atovaquone treatment are necessary. It is assumed that the use of adjunctive steroid therapy to reduce the respiratory complications with PCP is beneficial in non-HIV patients [<xref ref-type="bibr" rid="CR17">17</xref>]. This, with initiation of early diagnosis and the treatment, might explain the rare occurrence of fibrosis and the reversibility of architectural distortions. In the present case, repeated pulse methylprednisolone therapy was performed together with specific antibiotic therapy during the course of disease, but the effects were insufficient. Therefore, direct hemoperfusion using a polymyxin B-immobilized fiber column and intravenous cyclophosphamide therapy were added, because these treatments have sometimes been performed in cases of acute interstitial pneumonia [<xref ref-type="bibr" rid="CR18">18</xref>]. However, these treatments were not sufficient to arrest the progression of interstitial pneumonia.</p>
      <p>Prophylactic treatment for PCP with TMP/SMX should be considered for high-risk patients. However, a recent review considered that it was impossible to predict which patients would benefit the most from TMP/SMZ, and that thousands of subjects would need to be studied before the benefit of TMP/SMZ was proven [<xref ref-type="bibr" rid="CR19">19</xref>]. TMP/SMZ for prophylaxis might be considered in high-risk patients such as those with interstitial pneumonia and bronchiectasis.</p>
    </sec>
    <sec id="Sec4" sec-type="conclusion">
      <title>Conclusions</title>
      <p>The PCP is a potentially fatal condition in immunocompromised hosts. The architectural distortions of lung should be considered as a cause of death of PCP. For this reason, a high suspicion of this infectious complication must be kept in mind in order to establish an early diagnosis and treatment in patients with RA managed with MTX and biologics. Further accumulation of similar cases is needed to clarify the etiology and treatment of the architectural distortions.
</p>
    </sec>
  </body>
  <back>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>PCP</term>
          <def>
            <p><italic>Pneumocystis jirovecii</italic> pneumonia</p>
          </def>
        </def-item>
        <def-item>
          <term>RA</term>
          <def>
            <p>rheumatoid arthritis</p>
          </def>
        </def-item>
        <def-item>
          <term>AIDS</term>
          <def>
            <p>acquired immune deficiency syndrome</p>
          </def>
        </def-item>
        <def-item>
          <term>HIV</term>
          <def>
            <p>human immunodeficiency virus</p>
          </def>
        </def-item>
        <def-item>
          <term>ILD</term>
          <def>
            <p>interstitial lung disease</p>
          </def>
        </def-item>
        <def-item>
          <term>GGOs</term>
          <def>
            <p>ground glass opacities</p>
          </def>
        </def-item>
        <def-item>
          <term>CT</term>
          <def>
            <p>computed tomography</p>
          </def>
        </def-item>
        <def-item>
          <term>MTX</term>
          <def>
            <p>methotrexate</p>
          </def>
        </def-item>
        <def-item>
          <term>KL-6</term>
          <def>
            <p>sialylated carbohydrate antigen Krebs von den Lungen-6</p>
          </def>
        </def-item>
        <def-item>
          <term>SP-D</term>
          <def>
            <p>surfactant protein D</p>
          </def>
        </def-item>
        <def-item>
          <term>CEA</term>
          <def>
            <p>carcinoembryonic antigen</p>
          </def>
        </def-item>
        <def-item>
          <term>CA19-9</term>
          <def>
            <p>carbohydrate antigen 19-9</p>
          </def>
        </def-item>
        <def-item>
          <term>sIL-2R</term>
          <def>
            <p>soluble interleukin-2 receptor</p>
          </def>
        </def-item>
        <def-item>
          <term>HR-CT</term>
          <def>
            <p>high-resolution CT</p>
          </def>
        </def-item>
        <def-item>
          <term>SMX/TMP</term>
          <def>
            <p>trimethoprim/sulfamethoxazole</p>
          </def>
        </def-item>
        <def-item>
          <term>BAL</term>
          <def>
            <p>bronchoalveolar lavage</p>
          </def>
        </def-item>
        <def-item>
          <term>PCR</term>
          <def>
            <p>polymerase chain reaction</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <ack>
      <title>Authors&#x2019; contributions</title>
      <p>TK, HT, YN, HS, TN, YW and HM made substantial contributions to conception and acquisition of data and analysis and interpretation of data. MN and IN helped to draft the manuscript. All authors read and approved the final manuscript.</p>
      <sec id="FPar1">
        <title>Acknowledgements</title>
        <p>We would like to thank to Dr. Katsuaki Asakawa (Department of Respiratory Medichine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences) for helping to evaluate the radiographic images and all relevant medical staff in our Division of Clinical Nephrology and Rheumatology.</p>
      </sec>
      <sec id="FPar5">
        <title>Availability of data and materials</title>
        <p>The dataset supporting the conclusions of this article was included within the article and its additional file.</p>
      </sec>
      <sec id="FPar3">
        <title>Consent</title>
        <p>Written informed consent was obtained from husband of the patient for publication of this case report and any accompanying images.</p>
      </sec>
      <sec id="FPar2">
        <title>Competing interests</title>
        <p>The authors declare that they have no competing interests.</p>
      </sec>
      <sec id="FPar4">
        <title>Funding</title>
        <p>There was no research grant for this study.</p>
      </sec>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Koike</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Harigai</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Inokuma</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Inoue</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ishiguro</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Ryu</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Takeuchi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Tanaka</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Yamanaka</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Fujii</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Freundlich</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Suzukawa</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Postmarketing surveillance of the safety and effectiveness of etanercept in Japan</article-title>
          <source>J Rheumatol</source>
          <year>2009</year>
          <volume>36</volume>
          <fpage>898</fpage>
          <lpage>906</lpage>
          <pub-id pub-id-type="doi">10.3899/jrheum.080791</pub-id>
          <pub-id pub-id-type="pmid">19332630</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thomas</surname>
              <given-names>CF</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Limper</surname>
              <given-names>AH</given-names>
            </name>
          </person-group>
          <article-title>Pneumocystis pneumonia</article-title>
          <source>NEJM</source>
          <year>2004</year>
          <volume>350</volume>
          <fpage>2487</fpage>
          <lpage>2498</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMra032588</pub-id>
          <pub-id pub-id-type="pmid">15190141</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Turesson</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>O&#x2019;Fallon</surname>
              <given-names>WM</given-names>
            </name>
            <name>
              <surname>Crowson</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Gabriel</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Matteson</surname>
              <given-names>EL</given-names>
            </name>
          </person-group>
          <article-title>Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years</article-title>
          <source>Ann Rheum Dis</source>
          <year>2003</year>
          <volume>62</volume>
          <fpage>722</fpage>
          <lpage>727</lpage>
          <pub-id pub-id-type="doi">10.1136/ard.62.8.722</pub-id>
          <pub-id pub-id-type="pmid">12860726</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cimmino</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Salvarani</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Macchioni</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Montecucco</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Fossaluzza</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Mascia</surname>
              <given-names>MT</given-names>
            </name>
            <name>
              <surname>Punzi</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Davoli</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Filippini</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Numo</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Extra-articular manifestations in 587 Italian patients with rheumatoid arthritis</article-title>
          <source>Rheumatol Int</source>
          <year>2000</year>
          <volume>19</volume>
          <fpage>213</fpage>
          <lpage>217</lpage>
          <pub-id pub-id-type="doi">10.1007/PL00006853</pub-id>
          <pub-id pub-id-type="pmid">11063290</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cong</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>KS</given-names>
            </name>
            <name>
              <surname>Yi</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Chung</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>TS</given-names>
            </name>
            <name>
              <surname>Han</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Pulmonary fungal infection: imaging findings in immunocompetent and immunocompromised patients</article-title>
          <source>Eur J Radiol</source>
          <year>2006</year>
          <volume>59</volume>
          <fpage>371</fpage>
          <lpage>383</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ejrad.2006.04.017</pub-id>
          <pub-id pub-id-type="pmid">16725293</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Crans</surname>
              <given-names>CA</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Boiselle</surname>
              <given-names>PM</given-names>
            </name>
          </person-group>
          <article-title>Imaging features of <italic>Pneumocystis carinii</italic> pneumonia</article-title>
          <source>Crit Rev Diagn Imaging</source>
          <year>1999</year>
          <volume>40</volume>
          <fpage>251</fpage>
          <lpage>284</lpage>
          <pub-id pub-id-type="doi">10.3109/10408379991249194</pub-id>
          <pub-id pub-id-type="pmid">10514937</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Saldana</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Mones</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Martinez</surname>
              <given-names>GR</given-names>
            </name>
          </person-group>
          <article-title>The pathology of treated <italic>Pneumocystis carinii</italic> pneumonia</article-title>
          <source>Semin Diagn Pathol</source>
          <year>1989</year>
          <volume>6</volume>
          <fpage>300</fpage>
          <lpage>312</lpage>
          <pub-id pub-id-type="pmid">2678339</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gruden</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Turner</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Webb</surname>
              <given-names>WR</given-names>
            </name>
            <name>
              <surname>Merrifield</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Stansell</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Gamsu</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Hopewell</surname>
              <given-names>PC</given-names>
            </name>
          </person-group>
          <article-title>High-resolution CT in the evaluation of clinically suspected <italic>Pneumocystis carinii</italic> pneumonia in AIDS patients with normal equivocal or nonspecific radiographic findings</article-title>
          <source>AJR</source>
          <year>1997</year>
          <volume>169</volume>
          <fpage>967</fpage>
          <lpage>975</lpage>
          <pub-id pub-id-type="doi">10.2214/ajr.169.4.9308446</pub-id>
          <pub-id pub-id-type="pmid">9308446</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bergin</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Wirth</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Berry</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>Castellino</surname>
              <given-names>RA</given-names>
            </name>
          </person-group>
          <article-title><italic>Pneumocystis carinii</italic> pneumonia: CT and HRCT observations</article-title>
          <source>J Comput Assist Tomogr</source>
          <year>1990</year>
          <volume>14</volume>
          <fpage>756</fpage>
          <lpage>759</lpage>
          <pub-id pub-id-type="doi">10.1097/00004728-199009000-00014</pub-id>
          <pub-id pub-id-type="pmid">2398155</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vogel</surname>
              <given-names>MN</given-names>
            </name>
            <name>
              <surname>Brodoefel</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Hierl</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Beck</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Bethge</surname>
              <given-names>WA</given-names>
            </name>
            <name>
              <surname>Claussen</surname>
              <given-names>CD</given-names>
            </name>
            <name>
              <surname>Horger</surname>
              <given-names>MS</given-names>
            </name>
          </person-group>
          <article-title>Differences and similarities of cytomegalovirus and pneumocystis pneumonia in HIV-negative immunocompromised patients thin section CT morphology in the early phase of the disease</article-title>
          <source>Br J Radiol</source>
          <year>2007</year>
          <volume>80</volume>
          <fpage>516</fpage>
          <lpage>523</lpage>
          <pub-id pub-id-type="doi">10.1259/bjr/39696316</pub-id>
          <pub-id pub-id-type="pmid">17151065</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Harigai</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Koike</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Miyasaka</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>Pneumocystis pneumonia under anti-tumor necrosis factor therapy (PAT) study group. Pneumocystis pneumonia associated with infliximab in Japan</article-title>
          <source>N Engl J Med</source>
          <year>2007</year>
          <volume>357</volume>
          <fpage>1874</fpage>
          <lpage>1876</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMc070728</pub-id>
          <pub-id pub-id-type="pmid">17978303</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tasaka</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hasegawa</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Kobayashi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Yamada</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Nishimura</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Takeuchi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ishizaka</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Serum indicators for the diagnosis of pneumocystis pneumonia</article-title>
          <source>Chest</source>
          <year>2007</year>
          <volume>131</volume>
          <fpage>1173</fpage>
          <lpage>1180</lpage>
          <pub-id pub-id-type="doi">10.1378/chest.06-1467</pub-id>
          <pub-id pub-id-type="pmid">17426225</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mori</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sugimoto</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title><italic>Pneumocystis jirovecii</italic> Pneumonia in Rheumatoid Arthritis Patients: risks and Prophylaxis Recommendations</article-title>
          <source>Clin Med Insights Circ Respir Pulm Med</source>
          <year>2015</year>
          <volume>9</volume>
          <issue>Suppl 1</issue>
          <fpage>29</fpage>
          <lpage>40</lpage>
          <pub-id pub-id-type="pmid">26396551</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Boiselle</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Crans</surname>
              <given-names>CA</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Kaplan</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
          <article-title>The changing face of <italic>Pneumocystis carinii</italic> pneumonia in AIDS patients</article-title>
          <source>AJR</source>
          <year>1999</year>
          <volume>172</volume>
          <fpage>1301</fpage>
          <lpage>1309</lpage>
          <pub-id pub-id-type="doi">10.2214/ajr.172.5.10227507</pub-id>
          <pub-id pub-id-type="pmid">10227507</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kuhlman</surname>
              <given-names>JE</given-names>
            </name>
          </person-group>
          <article-title>Pneumocystis infections: the radiologist&#x2019;s perspective</article-title>
          <source>Radiology</source>
          <year>1996</year>
          <volume>1198</volume>
          <fpage>623</fpage>
          <lpage>635</lpage>
          <pub-id pub-id-type="doi">10.1148/radiology.198.3.8628844</pub-id>
          <pub-id pub-id-type="pmid">8628844</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tokuda</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Sakai</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Yamada</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Johkoh</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Imamura</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Dohi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hirakata</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Yamada</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kamatani</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Kikuchi</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Sugii</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Takeuchi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Tateda</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Goto</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Clinical and radiological features of Pneumocystis pneumonia in patients with rheumatoid arthritis, in comparison with methotrexate pneumonitis and Pneumocystis pneumonia in acquired immunodeficiency syndrome: a multicenter study</article-title>
          <source>Intern Med</source>
          <year>2008</year>
          <volume>47</volume>
          <fpage>915</fpage>
          <lpage>923</lpage>
          <pub-id pub-id-type="doi">10.2169/internalmedicine.47.0702</pub-id>
          <pub-id pub-id-type="pmid">18480575</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pareja</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Garland</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Koziel</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Use of adjunctive corticosteroids in severe adult non-HIV <italic>Pneumocystis carinii</italic> pneumonia</article-title>
          <source>Chest</source>
          <year>1998</year>
          <volume>113</volume>
          <fpage>1215</fpage>
          <lpage>1224</lpage>
          <pub-id pub-id-type="doi">10.1378/chest.113.5.1215</pub-id>
          <pub-id pub-id-type="pmid">9596297</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Enomoto</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Mikamo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Oyama</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Kono</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hashimoto</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Fujisawa</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Inui</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Nakamura</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Yasuda</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kato</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Mimuro</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Doi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sato</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Suda</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Treatment of acute exacerbation of idiopathic pulmonary fibrosis with direct hemoperfusion using a polymyxin B-immobilized fiber column improves survival</article-title>
          <source>BMC Pulm Med</source>
          <year>2015</year>
          <volume>15</volume>
          <fpage>15</fpage>
          <pub-id pub-id-type="doi">10.1186/s12890-015-0004-4</pub-id>
          <pub-id pub-id-type="pmid">25887940</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bodro</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Paterson</surname>
              <given-names>DL</given-names>
            </name>
          </person-group>
          <article-title>Has the time come for routine trimethoprim-sulfamethoxazole prophylaxis in patients taking biologic therapies?</article-title>
          <source>Clin Infect Dis</source>
          <year>2013</year>
          <volume>56</volume>
          <fpage>1621</fpage>
          <lpage>1628</lpage>
          <pub-id pub-id-type="doi">10.1093/cid/cit071</pub-id>
          <pub-id pub-id-type="pmid">23392396</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
